Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Castle Biosciences, Inc. CSTL
$22.63
-$0.06 (-0.26%)
На 18:01, 12 мая 2023
+81.18%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
606693249.00000000
-
week52high
36.10
-
week52low
15.58
-
Revenue
137039000
-
P/E TTM
-8
-
Beta
1.01282000
-
EPS
-2.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 20:30
Описание компании
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Outperform | Market Outperform | 09 авг 2022 г. |
| Baird | Outperform | Outperform | 09 авг 2022 г. |
| Keybanc | Overweight | Overweight | 11 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 мая 2022 г. |
| Baird | Outperform | Outperform | 10 мая 2022 г. |
| Baird | Outperform | Outperform | 03 ноя 2022 г. |
| Scotiabank | Sector Outperform | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BRADBURY DANIEL | D | 92805 | 140 | 02 февр 2023 г. |
| BRADBURY DANIEL | D | 92780 | 140 | 02 февр 2023 г. |
| BRADBURY DANIEL | D | 184539 | 420 | 02 февр 2023 г. |
| BRADBURY DANIEL | D | 92945 | 895 | 02 февр 2023 г. |
| BRADBURY DANIEL | D | 92920 | 895 | 02 февр 2023 г. |
| BRADBURY DANIEL | D | 184959 | 2684 | 02 февр 2023 г. |
| MAETZOLD DEREK J | D | 24393 | 698 | 01 февр 2023 г. |
| MAETZOLD DEREK J | D | 24401 | 698 | 01 февр 2023 г. |
| MAETZOLD DEREK J | D | 24399 | 699 | 01 февр 2023 г. |
| MAETZOLD DEREK J | D | 110825 | 1398 | 01 февр 2023 г. |
Новостная лента
Castle Biosciences, Inc. (CSTL) Q1 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 23:07
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Puneet Souda - SVB Catherine Schulte - Baird Mark Massaro - BTIG Sung Ji Nam - Scotiabank Operator Good afternoon, and welcome to Castle Biosciences First Quarter 2023 Conference Call. As a reminder, today's call is being recorded.
7 Value Stocks to Buy for Long-Term Growth
InvestorPlace
26 мар 2023 г. в 13:50
For investors that have the patience to ride out volatility in exchange for possible long-term upside, value stocks to buy that are discounted against book value may offer considerable intrigue. On paper, book value represents the difference between the company's total assets and total liabilities.
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Business Wire
14 мар 2023 г. в 07:00
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 22 at 2:15 p.m. Eastern.
Castle Biosciences, Inc. (CSTL) Q4 2022 Earnings Call Transcript
Seeking Alpha
03 мар 2023 г. в 17:50
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarter 2022 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
28 февр 2023 г. в 21:05
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 14.29% and 4.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?